MIM
CARM

MetLife Investment Management’s Carisma Therapeutics CARM Stock Holding History

MetLife Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,186
Closed -$60K – 2833
2023
Q3 		$60K Hold
14,186
– – ﹤0.01% 2803
2023
Q2 		$124K Buy
+14,186
New +$77.2K ﹤0.01% 2552
2021
Q3 		– Sell
-3,273
Closed -$302K – 2571
2021
Q2 		$302K Buy
+3,273
New +$209K ﹤0.01% 1884

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's CARM Position: Q4 2023 in Review

MetLife Investment Management sold out of Carisma Therapeutics (CARM) in Q4 2023, closing a stake of 14,186 shares — an estimated $60K sold.

MetLife Investment Management first reported a position in CARM in Q2 2021 and held it in 3 quarters. The position peaked at $302K in Q2 2021. 50 funds tracked by Wall St. Rank hold CARM as of Q4 2023.

  • MetLife Investment Management reported no remaining Carisma Therapeutics position as of Q4 2023 after selling out during the quarter.
  • MetLife Investment Management sold 14,186 Carisma Therapeutics shares in Q4 2023, an estimated $60K.
  • MetLife Investment Management first reported a position in Carisma Therapeutics in Q2 2021 and held it in 3 quarters.
  • MetLife Investment Management's Carisma Therapeutics position peaked at $302K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2023.

Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.